CliffBio
biologic

Zomacton

somatropin

Loss of exclusivityMarch 2024projected — 12-year biologic exclusivity estimate
CompanyFerring Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameZomacton
Active ingredientsomatropin
Strength10MG
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalMarch 2012
Marketing statusRx

More from Ferring Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Zomacton patent cliff — loss of exclusivity March 2024 | CliffBio